期刊名称：EXPERT OPINION ON EMERGING DRUGS ISSN： 1472-8214 出版频率： Quarterly 出版社： TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON, England, OXON, OX14 4RN   出版社网址： http://informahealthcare.com/ 期刊网址： http://informahealthcare.com/loi/emd 影响因子： 4.191 主题范畴： PHARMACOLOGY & PHARMACY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Expert Opinion on Emerging Drugs ranks #60 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases. Each review article is structured to include: Concise background to the subject matter Assessment of medical need for alternative or novel therapies Assessment of the market and anticipated changes over time Summary of current research goals Outline of the scientific rationale for the approach(es) considered< Analysis of the competitive environment Discussion of potential development issues The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseases The audience consists of pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners. Indexing Chemical Abstracts (CODEN: EOEDA3), EMBASE/Excerpta Medica, Index Medicus/Medline, Science Citation Index Expanded��? Current Contents/Life Sciences Instructions to Authors Guidelines_EOED.pdf Editorial Board Anti-infectives Casadevall A, Albert Einstein College of Medicine, USA Dalhoff A, Bayer AG, Germany De Clercq E, Rega Institute for Medical Research, Belgium Georgopapadakou NH, MethylGene, Canada Kaatz GW, Wayne State University, USA Ohemeng K, Paratek Pharmaceuticals, USA Anti-inflammatory Akdis C, Swiss Institute of Allergy and Asthma Research, Switzerland Bountra C, GlaxoSmithKline, UK Chantry D, ICOS Corp., USA Chikanza IC, The Royal London Hospital, UK Drakeman DL, Medarex, USA Goldman S, Wyeth, USA Gryglewski RJ, Jagiellonian University Medical College, Poland Lamont A, Catalyst Biomedica Ltd., UK Levy D, Scios, USA Manning A, Hoffman La Roche, USA Poordad F, California Pacific Medical Center, USA Cardiovascular, Renal, Endocrine & Metabolic De Vries P, Erasmus Univ., The Netherlands Ezrin A, Conjuchem, Canada Feuerstein G, Wyeth, USA Gaviraghi G, GlaxoSmithKline, Italy Gryglewski RJ, Jagiellonian University Medical College, Poland Levy D, Scios, USA Ohlstein E, GlaxoSmithKline, USA Suckling KE, GlaxoSmithKline, UK Uzan A, Aventis, France Waksman R, Washington Hospital Center, USA Central & Peripheral Nervous Systems Bountra C, GlaxoSmithKline, UK Emmerling MR, Pfizer Global R&D, USA Gaviraghi G, GlaxoSmithKline, Italy Grundemar L, AstraZeneca Lund R&D, Sweden Guilleminault C, Stanford Sleep Disorders Clinic, USA Newgreen D, Pfizer Global R&D, UK Patsalos PN, The National Hospital for Neurology & Neurosurgery, UK Sharma T, Clinical Neuroscience Research Centre, UK Sprouse J, Pfizer, USA Walker MC, University College, London, UK Zhang J, Guildford Pharmaceuticals, USA Oncologic, Endocrine & Metabolic Georgopapadakou NH, MethylGene, Canada Giles FJ, MD Anderson Cancer Center, USA Gorecki DC, Portsmouth Univ., UK Kumar CC, Schering-Plough Research Institute, USA Lengauer C, The Sidney Kimmel Comprehensive Cancer Center, USA Middleton MR, Christie Hospital, UK Nuttall ME, GlaxoSmithKline, USA Nyce J, EpiGenesis Pharmaceuticals, USA Perry C, Univ. of Glasgow, UK Petrie JR, Univ. of Glasgow, UK Santini D, University Campus Biomedico, Italy Sebolt-Leopold JS, Pfizer Global R&D, USA Vincenzi B, Campus Bio-Medico Univ., Italy Pulmonary-Allergy, Dermatology, Gastrointestinal & Arthritis  Barnes PJ, National Heart and Lung Institute, UK